---
schema_version: "secwatch.filing_event.v1"
accession: "0001753926-25-001766"
form_type: "8-K"
ticker: "PTHS"
cik: "0001919246"
company_name: "Pelthos Therapeutics Inc."
filed_at: "2025-11-13T23:59:59+00:00"
generated_at: "2026-05-16T20:36:53.501363+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Pelthos Q3: ZELSUVMI launch generates $7.1M net revenue, net loss $16.2M

## Summary
- Net product revenue of $7.1M from ZELSUVMI in first commercial quarter (Q3 ended Sep 30, 2025).
- 2,716 units prescribed by 1,169 unique prescribers; October alone saw 2,189 units prescribed.
- Net loss of $16.2M ($5.30 per basic/diluted share); as-converted net loss of $1.83/share.
- Cash of $14.2M at Sep 30, 2025; closed $18M convertible notes financing in Nov 2025.
- Completed acquisition of XEPI (FDA-approved impetigo treatment) in Nov 2025, adding complementary dermatology product.

## SEC filing metadata
- accession: 0001753926-25-001766
- form_type: 8-K
- ticker: PTHS
- cik: 0001919246
- company_name: Pelthos Therapeutics Inc.
- filed_at: 2025-11-13T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1919246/000175392625001766/0001753926-25-001766-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1919246/000175392625001766/g085015_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001753926-25-001766
- JSON: https://secwatch.observer/filing/0001753926-25-001766.json
- Plain text: https://secwatch.observer/filing/0001753926-25-001766.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.